PlumX Metrics
Embed PlumX Metrics

Harnessing Fc receptor biology in the design of therapeutic antibodies

Current Opinion in Immunology, ISSN: 0952-7915, Vol: 40, Page: 78-87
2016
  • 85
    Citations
  • 0
    Usage
  • 154
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    85
  • Captures
    154
  • Mentions
    1
    • News Mentions
      1
      • News
        1

Most Recent News

Fusing a Novel Anti-CTLA-4 Nanobody to the IgG1 Fc Region Strengthens Its Ability to Induce CD8+ T Cell-Mediated Immune Responses Against Solid Tumors

Introduction Adoptive cell therapy, in which autologous or allogeneic CD8+ T cells are exposed to tumor antigens in vitro and then injected into cancer patients,

Review Description

The antibody Fc domain engages the small family of Fc receptors, expressed on cells of the immune system and beyond, to stimulate a rich diversity of positive and negative cell-mediated effector functions. The emergence of monoclonal antibodies for the treatment of various pathologic conditions has provided additional insights into Fc receptor biology, and has suggested new strategies to exploit Fc receptor interactions to create improved therapeutics. While most therapeutic IgGs approved to date have retained a native IgG Fc domain, the knowledge gained over the last decades has provided the opportunity to design tailored and more efficacious immunotherapies exhibiting fewer side effects and longer half-life. This review summarizes recent advances made in the design of biologics that modulate or exploit Fc receptor-IgG interactions, and describes innovative drugs currently under investigation in clinical trials that have been precisely tuned to achieve a desired therapeutic effect.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know